Stroke AHA/ASA/X
Jun 12, 2025, 06:59
DOACs vs. Warfarin in Cerebral Venous Thrombosis: ACTION-CVT Study Shows Safer Profile Without Compromising Efficacy
Stroke AHA/ASA shared on X:
“STROKE In the Multicenter International Study ACTION CVT, patients with Cerebral Venous Thrombosis treated with DOACs had similar rate of thrombosis recurrence and recanalization rates, but lower risk of major hemorrhages, when compared to warfarin (1/3)”
Title: Low incidence of thromboembolism with Fiix-monitored warfarin compared to conventional warfarin and DOACs in patients with AF.
Authors: Arnar B. Ingason, Brynja R. Gudmundsdottir, Ragnar Palsson, Johann P. Hreinsson, Sigrun H. Lund, Loic R. Letertre, Edward Rumba, Arnar S. Agustsson, Einar S. Bjornsson, Pall T. Onundarson.
Read more about it in Blood Vessels, Thrombosis & Hemostasis (2025).
Discover more in Hemostasis Today.
Arnar B. Ingason
Arnar S. Agustsson
ASH
Blood Vessels
Brynja R. Gudmundsdottir
BVTH 2025
Cerebral Venous Thrombosis
DOACs
DOACs vs. Warfarin
Edward Rumba
Einar S. Bjornsson
Johann P. Hreinsson
Loic R. Letertre
Pall T. Onundarson.
Ragnar Palsson
Sigrun H. Lund
Study ACTION CVT
Thrombosis & Hemostasis
Thrombosis and Haemostasis
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda